Non-Clinical Safety Assessment for New Drugs

Comprehensive Evaluation of Drug Safety in Preclinical Studies

Non-clinical safety assessment is a critical step in the drug development process. These studies are designed to evaluate the potential risks of new pharmaceutical compounds before they enter human clinical trials. Regulatory agencies such as the FDA (USA) and EMA (EU) mandate comprehensive non-clinical safety studies as part of any New Drug Application (NDA) or Marketing Authorization Application (MAA). Conducted according to ICH non-clinical guidelines, these assessments aim to ensure a robust drug safety evaluation that supports clinical trial approval.

This article provides a comprehensive overview of the ICH non-clinical safety guidelines required for the preclinical safety assessment of new drugs. It also highlights how zebrafish models can complement traditional approaches in drug safety evaluation.

Key Components of Non-Clinical Safety Assessment of Pharmaceuticals

1. Safety Pharmacology (ICH S7A)

Safety pharmacology evaluates a drug’s potential effects on critical physiological systems to identify any acute, serious adverse effects. These studies determine two essential metrics:

• First in Human (FIH) Dose: The initial safe dose for clinical trials.
• No Observed Adverse Effect Level (NOAEL): The highest dose with no harmful effects.

Targeted organ systems include:

• Central Nervous System (CNS): Evaluates motor activity, sensory responses, and body temperature using the Functional Observation Battery (FOB).
• Cardiovascular System: Involves ECG analysis, heart rate, and blood pressure monitoring to detect repolarization or conduction abnormalities.
• Respiratory System: Measures respiratory rate and tidal volume using non-invasive technologies.

2. Pharmacokinetics and Toxicokinetics (ICH S3A, S3B)

These studies characterize the compound’s absorption, distribution, metabolism, and excretion (ADME):

Toxicokinetics (ICH S3A)

Links systemic exposure levels in animals to observed toxic effects, providing context for dose-response relationships.

Pharmacokinetics (ICH S3B)

Single-dose tissue distribution studies to provide information on distribution and accumulation of the compound and/or metabolites.

3. Toxicology Studies

Single-Dose Toxicity:

Assesses acute toxicity using two mammalian species, providing initial safety data.

Repeated-Dose Toxicity:

Evaluates chronic exposure risks and determines appropriate dosing schedules for clinical use.

Recommended Duration of Repeated-Dose Toxicity Studies to Support the Conduct of Clinical Trials

4. Genotoxicity (ICH S2 (R1))

Genotoxicity tests detect compounds causing genetic damage, which may lead to mutations, cancer, or heritable conditions.

Standard Battery Includes:

• Option 1:
  • A test for gene mutation in bacteria
  • A cytogenetic test for chromosomal damage
  • An in vivo test for genotoxicity
• Option 2:
  • A test for gene mutation in bacteria
  • An in vivo assessment of genotoxicity with two different tissues

5. Carcinogenicity (ICH S1A, S1B, S1C (R2))

Carcinogenicity studies investigate whether long-term exposure to a drug increases cancer risk. These are typically performed using rodent or transgenic models.

6. Reproductive and Developmental Toxicity (ICH S5 (R3))

These studies assess potential adverse effects on fertility, embryonic development, and offspring growth:

• Fertility and Early Embryonic Development (FEED): Evaluates effects on gamete function, fertilization, and implantation.
  Results from repeated-dose toxicity studies of at least two weeks duration can often be used to design the fertility study without conducting further dose ranging studies.
  
• Embryo-Fetal Development (EFD): Assesses embryo-fetal development and organogenesis.
  For most small molecules, effects on EFD are typically evaluated in two species (i.e., rodent and non-rodent (typically rabbit)). 
  
• Pre- and Postnatal Development (PPND): Monitors offspring growth and development post-birth.
  Since manifestations of effects induced during pregnancy can be delayed, development of the offspring is monitored through sexual maturity. The rodent is usually used to assess PPND; however, other species can be used as appropriate.

7. Immunotoxicity (ICH S8)

These studies identify drugs that may suppress or over-activate the immune system. Key indicators include changes in immune cell counts, spleen or thymus weight, immune organ histopathology, and increased tumor occurrence.

Zebrafish: A Complementary Model for Non-Clinical Safety Studies

While mammalian models remain the gold standard in ICH guidelines, zebrafish (Danio rerio) offer a complementary approach for early safety screenings. ZeClinics specializes in adapting zebrafish-based assays to align with traditional ICH endpoints, providing:

• Neurotoxicity, cardiotoxicity, and hepatotoxicity evaluations.
• Developmental and reproductive toxicity assessments.

These zebrafish-based toxicology assessments provide rapid, scalable insights and support ethical standards under the 3Rs principle. This makes them a valuable addition to the broader landscape of preclinical safety assessment.

Ready to Learn More?

Schedule a call with our experts to discover how ZeClinics can accelerate your pharmaceutical toxicology assessments. Let us help you bring safer and more effective drugs to market.

Contact Us Today

Conclusion

A robust non-clinical safety assessment framework is essential for drug safety evaluation before clinical trials. By integrating traditional mammalian studies with innovative zebrafish models, pharmaceutical developers can improve efficiency, reduce costs, and ensure ethical compliance. This harmonized approach supports a more reliable and predictive preclinical safety assessment, ultimately leading to safer and more effective medicines.

References

European Medicine Agency - Non-clinical guidelines

By Miriam Martínez

Miriam is a Human Biologist with a strong background in neuropharmacology and a passion for bridging science and innovation. After earning a master’s degree in the Pharmaceutical and Biotech Industry, she completed her PhD in Biomedicine at Pompeu Fabra University (Barcelona), where her research focused on the behavioral analysis of animal models for neurophenotypical characterization. Following her doctoral studies, Miriam transitioned into the healthcare marketing and communication sector, where she played a key role in developing impactful marketing strategies and educational campaigns for leading pharmaceutical brands. She now leverages her scientific expertise, strategic thinking, and creative communication skills in her current role at ZeClinics.